Oramed Pharmaceuticals Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the annual meeting of stockholders held by Oramed Pharmaceuticals Inc. on August 11, 2015. The company is incorporated in Delaware with principal executive offices in Jerusalem, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals during the annual meeting:
- Proposal No. 1: Re-election of Directors. All six nominees were re-elected. Significant broker non-votes (3,322,933) were recorded for each director, indicating shares held by brokers that were not voted due to lack of instructions.
- Nadav Kidron: 3,469,253 For; 101,687 Against; 14,717 Abstain.
- Miriam Kidron: 3,466,710 For; 102,596 Against; 16,351 Abstain.
- Leonard Sank: 3,492,857 For; 51,665 Against; 41,135 Abstain.
- Harold Jacob: 3,504,880 For; 39,942 Against; 40,835 Abstain.
- Michael Berelowitz: 3,467,144 For; 100,805 Against; 17,708 Abstain.
- Gerald Ostrov: 3,505,725 For; 39,497 Against; 40,435 Abstain.
- Proposal No. 2: Ratification of Auditors. Stockholders ratified the appointment of Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) as the independent registered public accounting firm for the fiscal year ending August 31, 2015.
- Votes: 6,699,311 For; 59,389 Against; 149,890 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Confirm the tenure of the re-elected directors and any potential conflicts of interest.
- Check for any subsequent filings regarding the audit firm's engagement letter or scope.